Thomas M Zydowsky
Overview
Explore the profile of Thomas M Zydowsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teleshova N, Keller M, Romero J, Friedland B, Creasy G, Plagianos M, et al.
PLoS One
. 2022 Jan;
17(1):e0261775.
PMID: 35051209
HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT's preclinical safety, lack of systemic absorption after...
2.
Mahoney O, Melo C, Lockhart A, Cornejal N, Alsaidi S, Wu Q, et al.
S Afr J Bot
. 2021 Dec;
146:735-739.
PMID: 34955582
Plant-based compounds with antiviral properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been identified in through computational models. The seed extract have been traditionally used to treat different...
3.
Alsaidi S, Cornejal N, Mahoney O, Melo C, Verma N, Bonnaire T, et al.
Mar Drugs
. 2021 Aug;
19(8).
PMID: 34436255
Over 182 million confirmed cases of COVID-19 and more than 4 million deaths have been reported to date around the world. It is essential to identify broad-spectrum antiviral agents that...
4.
5.
Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, et al.
Nat Commun
. 2018 Sep;
9(1):3881.
PMID: 30250170
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) strategies with proven in vivo efficacy rely on antiretroviral drugs, creating the potential for drug resistance and complicated treatment options in individuals who...
6.
7.
Mizenina O, Hsu M, Jean-Pierre N, Aravantinou M, Levendosky K, Paglini G, et al.
Drug Deliv Transl Res
. 2017 Aug;
7(6):859-866.
PMID: 28812250
We previously showed that the combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 with zinc acetate (ZA) formulated in a carrageenan (CG; MZC) gel provided macaques significant protection against...
8.
Derby N, Aravantinou M, Kenney J, Ugaonkar S, Wesenberg A, Wilk J, et al.
Drug Deliv Transl Res
. 2017 Jun;
7(6):840-858.
PMID: 28600625
Women globally need access to multipurpose prevention technologies (MPTs) that prevent human immunodeficiency virus (HIV), sexually transmitted infections that increase HIV acquisition/transmission risk, and unintended pregnancy. Seeking an MPT with...
9.
Calenda G, Villegas G, Barnable P, Litterst C, Levendosky K, Gettie A, et al.
J Acquir Immune Defic Syndr
. 2016 Aug;
74(3):e67-e74.
PMID: 27552154
The Population Council's microbicide gel MZC (also known as PC-1005) containing MIV-150 and zinc acetate dihydrate (ZA) in carrageenan (CG) has shown promise as a broad-spectrum microbicide against HIV, herpes...
10.
Friedland B, Hoesley C, Plagianos M, Hoskin E, Zhang S, Teleshova N, et al.
J Acquir Immune Defic Syndr
. 2016 Jul;
73(5):489-496.
PMID: 27437826
Objective: To evaluate the safety and pharmacokinetics of MIV-150 and zinc acetate in a carrageenan gel (PC-1005). Acceptability, adherence, and pharmacodynamics were also explored. Design: A 3-day open-label safety run-in...